Romu Corbau
Leuven, VLG, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Nonclinical study of ixo-vec gene therapy for nAMD supports efficacy for a human dose of 6E10 vg/eye and staggered dosing of fellow eyes.
Journal: Molecular therapy. Methods & clinical development
Published: March 20, 2024
1-((2,4-Dichlorophenethyl)Amino)-3-Phenoxypropan-2-ol Kills Pseudomonas aeruginosa through Extensive Membrane Damage.
Journal: Frontiers in microbiology
Published: September 15, 2017
Antibacterial Activity of 1-[(2,4-Dichlorophenethyl)amino]-3-Phenoxypropan-2-ol against Antibiotic-Resistant Strains of Diverse Bacterial Pathogens, Biofilms and in Pre-clinical Infection Models.
Journal: Frontiers in microbiology
Published: August 07, 2017
Identification of 1-((2,4-Dichlorophenethyl)Amino)-3-Phenoxypropan-2-ol, a Novel Antibacterial Compound Active against Persisters of Pseudomonas aeruginosa.
Journal: Antimicrobial agents and chemotherapy
Published: April 20, 2017
ANALYSIS OF THE MODE OF ACTION OF A PSEUDOMONAS AERUGINOSA ANTI-PERSISTER COMPOUND.
Journal: Communications in agricultural and applied biological sciences
Published: December 04, 2015
Identification and characterization of an anti-pseudomonal dichlorocarbazol derivative displaying anti-biofilm activity.
Journal: Bioorganic & medicinal chemistry letters
Published: July 25, 2014
Deep Sequencing Insights in Therapeutic shRNA Processing and siRNA Target Cleavage Precision.
Journal: Molecular therapy. Nucleic acids
Published: September 30, 2013
Synthesis and pharmacological evaluation of carboxycoumarins as a new antitumor treatment targeting lactate transport in cancer cells.
Journal: Bioorganic & medicinal chemistry
Published: June 12, 2013
Safe, long-term hepatic expression of anti-HCV shRNA in a nonhuman primate model.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: June 28, 2012
In vitro characterization of the activity of PF-05095808, a novel biological agent for hepatitis C virus therapy.
Journal: Antimicrobial agents and chemotherapy
Published: December 29, 2011
Showing 1-10 of 10
Last Updated: 09/26/2026